Chen et al. prepared and screened daratumumab (Dar) with a density of 3.2 for CD38-positive MM and developed a micellar drug delivery system loaded with CFZ named Dar3.2-PMs-CFZ. This evidence concerns the gene CD38 and Miyoshi myopathy.